Cellectis (CLLS) news
Recent news
Cellectis SA: Barclays cuts to underweight from overweight; cuts target price to $1.3 from $9
Barclays has revised its stance on Cellectis SA (NASDAQ: CLLS), downgrading the stock from overweight to underweight and lowering its price target from $9 to $1.30. The move reflects a shift in the firm’s assessment of the company’s outlook and market positioning. Previously, Barclays had initiated…
AInvest Wire · Sep 16, 2026Cellectis announces strategic transformation to in vivo gene editing company
AInvest Wire · Sep 14, 2026Cellectis to host conference call and webcast on September 14 to provide a business update
Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS) is set to host a conference call and webcast on September 14, 2026, to provide a business update to investors and stakeholders. The call will be part of the company’s ongoing engagement with the investment community, following its participation in…
AInvest Wire · Sep 11, 2026Cellectis - final Phase 1 Balli-1 data for Lasme-Cel to be presented June 13, 2026
Cellectis, a clinical-stage biotechnology company, is set to present final Phase 1 data for its CD22-directed allogeneic CAR-T therapy, Lasme-cel, at the EHA annual congress on June 13 . The data will be presented orally by Nitin Jain, M.D., from MD Anderson Cancer Center, during a session on…
AInvest Wire · Jun 9, 2026Allogene Therapeutics names Zachary Roberts as CEO
Allogene Therapeutics, Inc. (Nasdaq: ALLO) has appointed Zachary J. Roberts, M.D., Ph.D., as Executive Vice President of Research and Development, a role that includes oversight of the company’s clinical and pre-clinical programs. Dr. Roberts succeeds Rafael Amado, M.D., who has stepped down to…
AInvest Wire · May 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.